Bevacizumab Monoclonal Antibody from Germany
Bevacizumab (Avastin) is a humanized monoclonal antibody binding VEGF, used for colorectal and lung cancer treatments. HTS 3002.13.0010 covers this unmixed, biotech-produced immunological product not in retail packaging. It qualifies as a protein regulating immunological processes per chapter definitions.
Duty Rate — Germany → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Include potency assay results (e.g
• VEGF binding) in documentation for CBP review
• For EU-origin, leverage mutual recognition agreements to streamline FDA pre-approval